Kevetrin, our lead product candidate, is a small m

Kevetrin, our lead product candidate, is a small molecule compound proprietary to the Company. Its structure is distinct from other anti-cancer agents currently on the market. Kevetrin was discovered by the Company’s founder, Dr. Krishna Menon, and has been studied extensively (in vitro and in vivo) demonstrating potent anti-cancer activity against various cancer cell lines. Kevetrin’s recent success in a series of animal model experiments with drug-resistant cancer cell lines, has galvanized the Company to focus on Kevetrin’s development potential in this area. Kevetrin’s primary mechanism of action has been shown to be p53 activation which induces the expression of p21 and acts as an inhibitor of cell cycle progression. Activated p53 induces expression of PUMA and initiates apoptosis.

From Cellceutix website